SCHEMBL13946292

SCHEMBL13946292

C=CCOC(=O)C1=C(c2cn3cnc(SC)c3s2)[C@H](C)[C@@H]2[C@@H]([C@@H](C)O)C(=O)N12

nearest known ligand 0.41

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FAP Q12884 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7729782 0.88 FAP (0.38) FAP
SCHEMBL7734482 0.86 FAP (0.36) FAP
SCHEMBL7729293 0.86 FAP (0.47) FAP
SCHEMBL6893606 0.86 CACNA1C (0.34)
SCHEMBL6772192 0.86 CACNA1C (0.34)
SCHEMBL6895949 0.86 CACNA1C (0.34)
SCHEMBL6770488 0.86 CACNA1C (0.34)
SCHEMBL7730149 0.85 FAP (0.36) FAP
SCHEMBL7722211 0.85 FAP (0.36) FAP
SCHEMBL7732680 0.85 FAP (0.36) FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482445-B2 Crystalline carbapenem intermediate MEIJI SEIKA KAISHA, LTD. (JP) 2009-01-27 US disclosed
US-7482445-B2 Crystalline carbapenem intermediate MEIJI SEIKA KAISHA, LTD. (JP) 2009-01-27 US disclosed
US-20070167620-A1 Crystalline carbapenem intermediate MEIJI SEIKA KAISHA, LTD. (JP) 2007-07-19 US disclosed
US-20070167620-A1 Crystalline carbapenem intermediate MEIJI SEIKA KAISHA, LTD. (JP) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167620-A1 Crystalline carbapenem intermediate TBKBP1, RPS6KB1, TNKS1BP1 FAP 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.